首頁 > 市場調查報告書 > 製藥

個人化醫學

市場調查報告書

商品編碼

2126359

EGFR伴隨診斷市場：策略洞察與預測（2026-2035年）

EGFR Companion Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月05日 | 出版商:

Knowledge Sourcing Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計 EGFR 伴隨診斷市場將從 2026 年的 18.9 億美元成長到 2035 年的 48.2 億美元，複合年成長率為 11.0%。

EGFR伴隨診斷市場正經歷顯著的變革，這主要得益於精準腫瘤學模式轉移以及EGFR標靶治療的廣泛應用。這一市場演變的特點是，人們日益認知到準確識別EGFR突變對於制定治療策略至關重要，尤其是在包括非小細胞肺癌在內的多種癌症類型中。聚合酵素鏈鎖反應（PCR）、次世代定序和液態生物檢體等先進分子技術的整合，使得EGFR突變檢測更快速、更全面、更方便。隨著基於生物標記的療法不斷展現出更佳的治療效果，分子檢測正從治療過程的早期階段就被納入醫療保健系統。製藥業的創新持續拓展著EGFR標靶治療的選擇，也使得人們越來越依賴能夠識別具有檢驗意義的基因組突變的已驗證診斷平台。由於治療效果直接取決於突變檢測的準確性，監管機構正根據標靶治療的發展不斷調整伴隨診斷的核准流程。隨著對綜合基因組分析、液態生物檢體技術和人工智慧分析工具的大量投資，EGFR伴隨診斷正在成為全球醫療保健系統中精準腫瘤學的關鍵組成部分。

市場促進因素

EGFR標靶治療的日益普及是EGFR伴隨診斷市場的主要驅動力。 EGFR伴隨診斷仍然至關重要，因為標靶治療需要在開始治療前進行分子層面的確認。隨著精準腫瘤學在臨床實踐中日益普及，製藥公司正在擴展其以EGFR為重點的治療產品組合。隨著治療專業化程度的提高，所有腫瘤治療領域對精準突變檢測的需求都在成長。診斷公司正在加強其檢測平台，以跟上不斷發展的治療路徑。這一趨勢正在增強對伴隨診斷的長期需求，並推動EGFR伴隨診斷的持續成長。全面基因組分析的日益普及透過提高治療選擇的準確性，進一步加速了市場成長。全面基因組分析透過同時評估多個臨床相關突變來提高治療選擇的準確性。隨著癌症治療變得更加個人化，醫療機構正在採用更廣泛的分子檢測策略。序貫檢測方法通常會導致效率低下，進而延誤治療決策。為了應對這些挑戰，診斷技術開發公司正在擴展其次世代定序(NGS) 能力。這一發展趨勢正在推動對先進基因組檢測解決方案的需求。隨著抗藥性突變檢測變得日益重要，伴隨診斷的臨床效用正在疾病的整個進展過程中不斷擴展。治療抗藥性會影響長期療效，因為後天突變會降低治療效果。臨床醫師越來越重視監測抗藥性相關的基因組突變，以最佳化後續治療策略。傳統的基準檢測通常無法提供疾病整個進展過程中所需的足夠資訊。診斷設備製造商正在開發相關技術，以支援對突變進行長期評估。這種日益成長的需求正在擴大伴隨診斷的臨床效用。監管機構對精準醫療的支持，透過強調生物標記檢驗，正在推動市場擴張。伴隨診斷透過分子檢測識別最有可能從標靶治療中獲益的患者，從而支持安全有效的治療。隨著癌症治療日益專業化，監管機構越來越關注生物標記的檢驗。監管力度的加強正在催生對經臨床檢驗的檢測解決方案的需求。

市場限制因素

先進分子檢測的高成本可能會限制其在報銷額度有限的醫療系統中的應用。先進技術所需的大量資金投入對小規模的醫療機構和發展中地區構成障礙。分子檢測基礎設施的差異可能會限制某些醫療市場獲得標準化EGFR診斷服務。專業實驗室和訓練有素的人員短缺限制了分子診斷的擴充性。監管和檢驗要求增加了伴隨診斷試劑生產商的研發複雜性，並延長了產品上市時間。嚴格的證據要求給開發商帶來了巨大的時間和成本負擔。不同司法管轄區法規的複雜性也給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

市場定義和範圍
EGFR標靶腫瘤學概述
產業變化
主要市場趨勢
市場規模表現分析
市場預測分析
疾病負擔與未滿足需求的分析
EGFR突變癌症的流行病學和盛行率分析
已確診患者族群的分析
對 EGFR 檢測數量的分析
精準腫瘤學採納現況分析
目前治療狀況及伴隨診斷的整合

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

EGFR檢測領域的新興技術
產品創新趨勢
臨床試驗分析
EGFR伴隨診斷的流程分析
整合次世代定序
液態生物檢體和ctDNA檢測技術的創新
將人工智慧整合到基因組分析中
技術藍圖

第7章監理情勢

法律規範
核准流程
合規要求

第8章：EGFR伴隨診斷市場：展望分析

分析：按技術平台
分析：依生物標記類型
分析：檢體類型
分析：透過臨床應用
分析：透過測試方法
分析：按癌症適應症

第9章：EGFR伴隨診斷市場：細分市場分析

透過技術
- 聚合酵素鏈鎖反應（PCR）
- 次世代定序（NGS）
- 桑格定序
- 螢光原位雜合反應（FISH）
- 免疫組織化學（IHC）
- 其他技術
癌症適應症類型
- 非小細胞肺癌（NSCLC）
- 結腸癌
- 膠質母細胞瘤
- 頭頸癌
- 其他固體癌
按突變類型
- 埃克森-19號失踪
- L858R突變
- T790M突變
- 第20外顯子插入突變
- 其他EGFR突變
依檢體類型
- 組織切片檢查
- 液態生物檢體
最終用戶
- 醫院
- 臨床實驗室
- 學術研究機構
- 專科癌症中心

第10章：EGFR伴隨診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章 EGFR伴隨診斷市場：國家分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
韓國
澳洲
印度
巴西
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
QIAGEN NV
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
Illumina, Inc.
Abbott Laboratories
Bio-Rad Laboratories, Inc.
Danaher Corporation
Guardant Health, Inc.
Foundation Medicine, Inc.
NeoGenomics Laboratories, Inc.
Sysmex Corporation
Myriad Genetics, Inc.
Leica Biosystems Nussloch GmbH
PERSONALIS, INC.

第14章 EGFR伴隨診斷市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009070

The EGFR Companion Diagnostics Market is anticipated to grow at a CAGR of 11.0% from USD 1.89 billion in 2026 to USD 4.82 billion in 2035.

The EGFR companion diagnostics market is undergoing significant transformation driven by the paradigm shift toward precision oncology and the expanding availability of EGFR-targeted therapies. The market's evolution is characterized by the growing recognition that accurate identification of EGFR mutations is essential for therapeutic decision-making across multiple cancer types, particularly non-small cell lung cancer. The convergence of advanced molecular technologies, including polymerase chain reaction, next-generation sequencing, and liquid biopsy, is enabling faster, more comprehensive, and increasingly accessible EGFR mutation detection. Healthcare systems are incorporating molecular testing earlier in treatment pathways as evidence increasingly demonstrates improved outcomes associated with biomarker-guided interventions. Pharmaceutical innovation continues expanding EGFR-directed therapeutic options, creating greater dependence on validated diagnostic platforms capable of identifying actionable genomic alterations. Regulatory agencies continue aligning companion diagnostic approvals with targeted therapy development because treatment outcomes depend directly on accurate mutation detection. The market is witnessing significant investment in comprehensive genomic profiling, liquid biopsy technologies, and AI-enabled interpretation tools, positioning EGFR companion diagnostics as a critical component of precision oncology across global healthcare systems.

Market Drivers

The expanding use of EGFR-targeted therapies represents the primary driver for the EGFR companion diagnostics market. EGFR companion diagnostics remain essential because targeted therapies require molecular confirmation before treatment initiation. Pharmaceutical developers are expanding EGFR-focused treatment portfolios as precision oncology becomes more integrated into clinical practice. Greater therapeutic specialization increases demand for accurate mutation detection across oncology care settings. Diagnostic companies are enhancing testing platforms to support evolving treatment pathways. This trend strengthens long-term demand for companion diagnostics, resulting in sustained growth in EGFR companion diagnostic utilization. The increasing adoption of comprehensive genomic profiling is further accelerating market growth through improved therapeutic selection. Comprehensive genomic profiling improves therapeutic selection because multiple clinically actionable alterations can be evaluated simultaneously. Healthcare providers are incorporating broader molecular testing strategies as cancer treatment becomes increasingly personalized. Sequential testing approaches often create inefficiencies that delay treatment decisions. Diagnostic developers are expanding NGS capabilities to address these limitations. This evolution reinforces demand for advanced genomic testing solutions. The growing importance of resistance mutation detection is expanding the clinical utility of companion diagnostics throughout disease progression. Treatment resistance influences long-term outcomes because acquired mutations can reduce therapeutic effectiveness. Clinicians are increasingly monitoring resistance-associated genomic alterations to optimize subsequent treatment strategies. Traditional baseline testing alone often provides insufficient information throughout disease progression. Diagnostic manufacturers are developing technologies that support longitudinal mutation assessment. This requirement expands the clinical utility of companion diagnostics. Regulatory support for precision medicine is sustaining market expansion through emphasis on biomarker validation. Companion diagnostics support safe and effective therapy utilization because molecular testing identifies patients most likely to benefit from targeted interventions. Regulatory agencies are increasing emphasis on biomarker validation as oncology therapies become more specialized. Greater regulatory scrutiny creates demand for clinically validated testing solutions.

Market Restraints

High costs associated with advanced molecular testing can limit adoption in healthcare systems with constrained reimbursement frameworks. The significant financial investment required for advanced technologies creates barriers for smaller facilities and developing regions. Variability in molecular testing infrastructure can restrict access to standardized EGFR diagnostics across certain healthcare markets. The shortage of specialized laboratories and trained personnel limits the scalability of molecular diagnostics. Regulatory and validation requirements increase development complexity and commercialization timelines for companion diagnostic manufacturers. The rigorous evidence requirements create significant time and cost burdens for developers. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of comprehensive genomic profiling and integrated molecular testing platforms. PCR remains widely adopted because many clinically actionable EGFR mutations require rapid and targeted detection before treatment initiation. Demand is shifting toward NGS because broader genomic profiling provides additional insights beyond individual EGFR alterations. Single-gene testing approaches often limit molecular understanding when multiple actionable biomarkers coexist within the same tumor. Clinical laboratories are expanding NGS implementation to improve testing efficiency and support comprehensive precision oncology programs. Sanger sequencing remains important for confirmation and research applications. FISH and IHC continue supporting specific alteration detection where applicable. Liquid biopsy is expanding testing accessibility through non-invasive mutation detection. The segment analysis reveals that NSCLC remains the largest application because EGFR mutations directly influence treatment selection and therapeutic outcomes. Expanding biomarker research is increasing demand across colorectal cancer, glioblastoma, and head and neck cancers as additional clinical applications emerge. Exon 19 Deletion and L858R mutations remain highly important because many approved EGFR-targeted therapies demonstrate efficacy within these patient populations. Resistance monitoring is increasing demand for T790M mutation testing as disease progression frequently involves acquired molecular changes. Tissue biopsy remains the clinical reference standard for EGFR mutation detection. Liquid biopsy is expanding for minimally invasive testing when tissue samples are limited, supporting longitudinal disease monitoring. Clinical diagnostic laboratories represent the leading end-user segment, with hospitals and specialty cancer centers expanding testing capabilities. The integration of AI is becoming increasingly important because genomic complexity increases interpretation challenges. Technology providers are incorporating AI into genomic platforms to enhance clinical decision support.

Competitive and Strategic Outlook

The competitive landscape features established diagnostics and life science companies alongside specialized precision oncology and liquid biopsy providers. Roche remains strategically distinct because it combines leadership in oncology therapeutics with one of the most established companion diagnostics portfolios in precision medicine, continuing to advance molecular diagnostic capabilities through the cobas platform and precision oncology initiatives that align closely with pharmaceutical development programs. QIAGEN differentiates itself through extensive expertise in molecular diagnostics, sample preparation technologies, and biomarker-driven testing solutions, continuing to develop molecular assays and pharmaceutical collaborations that support precision medicine strategies. Thermo Fisher Scientific maintains strategic relevance because its life sciences and diagnostics portfolio supports genomic analysis, molecular testing, and clinical laboratory operations, continuing to enhance sequencing technologies and oncology-focused diagnostic solutions. Agilent remains an important market participant because its pathology and molecular diagnostic capabilities support biomarker assessment across oncology applications, continuing to invest in diagnostic technologies that support workflow efficiency and clinical confidence. Illumina remains strategically important because NGS increasingly supports comprehensive genomic characterization within oncology, continuing to advance sequencing platforms that support companion diagnostic applications and precision oncology initiatives. Abbott maintains relevance through a diversified diagnostics portfolio that supports molecular testing and personalized healthcare initiatives, continuing to invest in diagnostic innovation that aligns with evolving precision medicine requirements. Bio-Rad contributes to the market through molecular diagnostic technologies that support mutation detection and analytical precision. Companies are pursuing product portfolio expansion through innovation in NGS panels, liquid biopsy assays, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside targeted therapies. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The EGFR companion diagnostics market is positioned for sustained growth driven by the convergence of targeted therapy expansion, comprehensive genomic profiling, and technological innovation. The transition from single-gene testing toward comprehensive genomic profiling represents a fundamental shift in precision oncology. While challenges related to high costs, infrastructure limitations, and regulatory complexity persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with EGFR companion diagnostics evolving into a critical component of precision oncology, supporting accurate patient stratification, treatment optimization, and improved clinical outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. EGFR Companion Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 EGFR-Driven Oncology Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast Analysis (2026-2035)
3.7 Disease Burden and Unmet Clinical Needs Analysis
3.8 Epidemiology and Prevalence Analysis of EGFR-Mutated Cancers
3.9 Diagnosed Patient Population Analysis
3.10 EGFR Testing Volume Analysis
3.11 Precision Oncology Adoption Analysis
3.12 Treatment Landscape and Companion Diagnostic Integration

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies in EGFR Testing
6.2 Product Innovation Trends
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis of EGFR Companion Diagnostics
6.5 Next-Generation Sequencing Integration
6.6 Liquid Biopsy Innovation and ctDNA Testing
6.7 AI Integration in Genomic Interpretation
6.8 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. EGFR Companion Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Biomarker Type
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Testing Methodology
8.6 Analysis by Cancer Indication

9. EGFR Companion Diagnostics Market Segment Analysis (2021-2035)

9.1 By Technology
- 9.1.1 Polymerase Chain Reaction (PCR)
- 9.1.2 Next-Generation Sequencing (NGS)
- 9.1.3 Sanger Sequencing
- 9.1.4 Fluorescence In Situ Hybridization (FISH)
- 9.1.5 Immunohistochemistry (IHC)
- 9.1.6 Other Technologies
9.2 By Cancer Indication
- 9.2.1 Non-Small Cell Lung Cancer (NSCLC)
- 9.2.2 Colorectal Cancer
- 9.2.3 Glioblastoma
- 9.2.4 Head and Neck Cancers
- 9.2.5 Other Solid Tumors
9.3 By Mutation Type
- 9.3.1 Exon 19 Deletion
- 9.3.2 L858R Mutation
- 9.3.3 T790M Mutation
- 9.3.4 Exon 20 Insertions
- 9.3.5 Other EGFR Mutations
9.4 By Sample Type
- 9.4.1 Tissue Biopsy
- 9.4.2 Liquid Biopsy
9.5 By End User
- 9.5.1 Hospitals
- 9.5.2 Clinical Diagnostic Laboratories
- 9.5.3 Academic and Research Institutes
- 9.5.4 Specialty Cancer Centers